1. PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections 
Enrico Munari, MD, PhD, Giuseppe Zamboni, MD, Gianluigi Lunardi, MPharm, Luigi Marchionni, MD, PhD, Marcella Marconi, BS, Marco Sommaggio, BS, Matteo Brunelli, MD, PhD, Guido Martignoni, MD, George J. Netto, MD, Mohammad O. Hoque, PhD, Francesca Moretta, MD, Maria Cristina Mingari, PhD, Maria Cristina Pegoraro, MD, Alessandro Inno, MD, Simona Paiano, MD, Alberto Terzi, MD, Alberto Cavazza, MD, Giulio Rossi, MD, Francesca Romana Mariotti, PhD, Paola Vacca, PhD, Lorenzo Moretta, MD, Giuseppe Bogina, MD 
Journal of Thoracic Oncology 
Volume 13, Issue 8, Pages (August 2018)
DOI: /j.jtho
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Representative image for heterogeneity of programmed death ligand 1 (PD-L1) expression. Whole section of squamous cell carcinoma of the lung stained with PD-L1 showing spots corresponding to tissue microarray cores numbered 1 to 5. Cores numbered 1 to 4 were sampled randomly in an area with a negative result when tested, whereas the result of testing of core 5 was positive in more than 50% of neoplastic cells. Overall, testing of the whole tumor yielded a result of PD-L1 expression in 20% of neoplastic cells.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions